Donald Mahler
- Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE studyBy Donald A. Mahler, Marc Decramer, Anthony D'Urzo, Heinrich Worth, Tracy White, Vijay K.T. Alagappan, Hungta Chen, Nicola Gallagher, Károly Kulich and Donald BanerjiDonald A. Mahler1Section of Pulmonary and Critical Care Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH, USAMarc Decramer2Division of Respiratory Medicine, University Hospital, Katholieke Universiteit, Leuven, BelgiumAnthony D'Urzo3Dept of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, CanadaHeinrich Worth4Dept of Pneumology and Cardiology, Hospital Fürth, University Erlangen-Nürnberg, Fürth, GermanyTracy White5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAVijay K.T. Alagappan5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAHungta Chen5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USANicola Gallagher6Novartis Horsham Research Centre, Horsham, UKKároly Kulich7Novartis Pharma AG, Basel, SwitzerlandDonald Banerji5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- Effectiveness of indacaterol and tiotropium in patients with severe dyspnoeaBy Donald Mahler, Roland Buhl, David Lawrence and Danny McBryanDonald Mahler1Section of Pulmonary & Critical Care Medicine, Dartmouth Medical School, Lebanon, NH, United StatesRoland Buhl2Pulmonary Department, Mainz University Hospital, Mainz, GermanyDavid Lawrence3Respiratory Department, Novartis Horsham Research Centre, Horsham, United KingdomDanny McBryan4Respiratory Department, Novartis Pharma AG, Basel, Switzerland
- Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE studyBy Donald A. Mahler, Marc Decramer, Anthony D'Urzo, Heinrich Worth, Tracy White, Vijay Alagappan, Hungta Chen, Karoly Kulich, Nicola Gallagher and Donald BanerjiDonald A. Mahler1Department of Medicine, Geisel School of Medicine, Dartmouth, Hanover, United StatesMarc Decramer2Department of Respiratory Medicine, University Hospital, Katholieke Universiteit, Leuven, BelgiumAnthony D'Urzo3Department of Family and Community Medicine, University of Toronto, Toronto, CanadaHeinrich Worth4Departments of Pulmonology and Cardiology, Hospital Fürth, University Erlangen-Nürnberg, Fürth, GermanyTracy White5Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesVijay Alagappan5Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen5Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesKaroly Kulich6Primary Care, Novartis Pharma AG, Basel, SwitzerlandNicola Gallagher7Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomDonald Banerji5Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Antagonism of substance P and perception of dyspnea in patients with COPDBy Donald Mahler, Alex Gifford, Laurie Waterman, Aamir Gilani, Brian Kupchak and Willian KraemerDonald Mahler1Section of Pulmonary & Critical Care Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, United StatesAlex Gifford1Section of Pulmonary & Critical Care Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, United StatesLaurie Waterman1Section of Pulmonary & Critical Care Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, United StatesAamir Gilani1Section of Pulmonary & Critical Care Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, United StatesBrian Kupchak2Kinesiology and Physiology and Neurobiology, University of Connecticut, Storrs, CT, United StatesWillian Kraemer2Kinesiology and Physiology and Neurobiology, University of Connecticut, Storrs, CT, United States
- Development and validation of an innovative self-administered computerized (SAC) version of baseline/transition dyspnea index (BDI/TDI) for evaluating breathlessness in patients with COPD: The BLAZE studyBy Donald A. Mahler, Vanessa Brunel, Tracy White, Vijay Alagappan, Hungta Chen, Karoly Kulich, Nicola Gallagher and Donald BanerjiDonald A. Mahler1Department of Medicine, Geisel School of Medicine, Dartmouth, Hanover, United StatesVanessa Brunel2Linguistic Validation, MAPI Institute, Lyon, FranceTracy White3Primary Care, Novartis Pharmaceutical Corporation, East Hanover, NJ, United StatesVijay Alagappan3Primary Care, Novartis Pharmaceutical Corporation, East Hanover, NJ, United StatesHungta Chen3Primary Care, Novartis Pharmaceutical Corporation, East Hanover, NJ, United StatesKaroly Kulich4Primary Care, Novartis Pharma AG, Basel, SwitzerlandNicola Gallagher5Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomDonald Banerji3Primary Care, Novartis Pharmaceutical Corporation, East Hanover, NJ, United States
- Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE studyBy Donald A Mahler, Marc Decramer, Anthony D'Urzo, Heinrich Worth, Tracy White, Vijay K. T. Alagappan, Hungta Chen, Nicola Gallagher, Károly Kulich and Donald BanerjiArticle | Published in 2013 in European Respiratory JournalDonald A Mahler*Section of Pulmonary & Critical Care Medicine; Geisel School of Medicine at Dartmouth; Hanover, NH, USAMarc Decramer#Division of Respiratory Medicine, University Hospital, Katholieke Universiteit, Leuven, BelgiumAnthony D'Urzo¶Dept of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, CanadaHeinrich Worth+Depts of Pneumology and Cardiology, Hospital Fürth, University Erlangen-Nürnberg, Fürth, GermanyTracy White§Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAVijay K. T. Alagappan§Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAHungta Chen§Novartis Pharmaceuticals Corporation, East Hanover, NJ, USANicola GallagherfNovartis Horsham Research Centre, Horsham, UKKároly Kulich**Novartis Pharma AG, Basel, SwitzerlandDonald Banerji§Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE studyBy Anthony D'Urzo, Donald A. Mahler, Caglar Karakurum, Hungta Chen, Robert Fogel and Donald BanerjiAnthony D'Urzo1Department of Family and Community Medicine, University of Toronto, Toronto, ON, CanadaDonald A. Mahler2Section of Pulmonary and Critical Care Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH,Caglar Karakurum3Primary Care, Novartis Pharma AG, Basel, SwitzerlandHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Robert Fogel4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Donald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,
- Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE studyBy Anthony D'Urzo, Donald A. Mahler, Petter Olsson, Hungta Chen, Robert Fogel and Donald BanerjiAnthony D'Urzo1Department of Family and Community Medicine, University of Toronto, Toronto, ON, CanadaDonald A. Mahler2Section of Pulmonary & Critical Care Medicine, Geisel School of Medicine, Dartmouth, NH,Petter Olsson3Primary Care, Novartis Pharma AG, Basel, SwitzerlandHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Robert Fogel4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Donald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,
- QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trialsBy Donald Mahler, Dorothy Keininger, Robert Fogel, Karen Mezzi and Donald BanerjiDonald Mahler1Medicine, Geisel School of Medicine, Hanover, NH United StatesDorothy Keininger2Respiratory, Novartis Pharma AG, Basal, SwitzerlandRobert Fogel3Respiratory, Novartis Pharmaceuticals Corporation, East Hanover, NJ United StatesKaren Mezzi2Respiratory, Novartis Pharma AG, Basal, SwitzerlandDonald Banerji3Respiratory, Novartis Pharmaceuticals Corporation, East Hanover, NJ United States
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.